Präsentation
Filtern
Dokumenttyp
- Zeitschriftenartikel (2) (entfernen)
Sprache
- Englisch (2)
Referierte Publikation
- ja (2)
Schlagworte
Organisationseinheit der BAM
Recent recommendations by the Food and Drug Administration1 and the European Medicines Agency2 are to limit the clinical use of linear gadolinium-based contrast agents (GBCAs) due to convincing evidence of deposition in tissues. Macrocyclic GBCA continued to be considered safe, provided that patients have normal renal function. To date, given the low sensitivity of conventional MRI, there has been a debate about the signal increase following the injections of a macrocyclic GBCA.
In this work, a study of electrochemical conversion was performed to elucidate different degradation pathways of the heterocyclic brominated flame retardants 1,3,5-Tris-(2,3-dibromopropyl)-1,3,5-triazine-2,4,6-trione (TDBP-TAZTO) and 2,4,6-Tris-(2,4,6-tribromo-phenoxy)-1,3,5-triazine (TTBP-TAZ). EC/MS was used to simulate the (bio)-transformation processes and to identify possible transformation products (TPs) which have never been reported before. For TDBP-TAZTO, six new TPs were observed after the electrochemical oxidation (applied potential of 0 to 1,800 mV vs. Pd/H2). In case of TTBP-TAZ, seven debromination products were generated with an applied potential of 0 to 2,200 mV vs. Pd/H2. The main degradation pathways confirmed by high resolution mass spectrometry for both compounds were hydroxylation, debromination as well as dehydrobromination.